Last reviewed · How we verify
NCT03112330: ARPRP
A Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Atrophic Rhinitis
NA trial testing Plasma rich platelet injection in Atrophic Rhinitis in 22 participants. Completed in 1 April 2019.
1 April 2019
Quick facts
| Lead sponsor | Seoul St. Mary's Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 8 June 2017 |
| Primary completion | 1 April 2019 |
| Estimated completion | 1 April 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Plasma rich platelet injection
- Saline nasal spray — full drug profile →
Conditions studied
- Atrophic Rhinitis — all drugs for Atrophic Rhinitis →
Sponsor
Seoul St. Mary's Hospital
Who can join
19 and older, any sex, with Atrophic Rhinitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of the suggested research is to develop a treatment option using platelet rich plasma injection for regeneration of atropic nasal mucosa. Specific aims of the suggested research is to (1) access the effect of platelet rich plasma in the patients with atropic rhinitis . Moreover, we will (2) compare the conservative treatments including saline nasal irrigation or saline nasal spray.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03112330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Seoul St. Mary's Hospital trials
Trials by the same sponsor.
- NCT07345026 — Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients · NA · not yet recruiting
- NCT07380867 — Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorec · NA · enrolling by invitation
- NCT07240844 — Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy · Phase 4 · not yet recruiting
- NCT06769087 — Comparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery · NA · enrolling by invitation
- NCT06442111 — The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03112330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul St. Mary's Hospital
- Last refreshed: 4 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03112330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing